Latest news with #LeerinkPartnersGlobalHealthcareConference
Yahoo
07-03-2025
- Business
- Yahoo
Progyny, Inc. to Participate in Upcoming Investor Conferences
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced it expects to participate in several upcoming investor conferences. Progyny executives will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on Monday, March 10, 2025, at 11:20 a.m. Eastern Time. The executives will then be participating in meetings at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on Tuesday, March 11, 2025. Pete Anevski, Chief Executive Officer, will also participate in a virtual fireside chat at the KeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, 2025, at 2:15 p.m. Eastern Time. A live audiocast and replay of the fireside chats will be available from the Events and Presentations section of Progyny's website at About ProgynyProgyny (Nasdaq: PGNY) is a transformative fertility, family building and women's health benefits solution, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@
Yahoo
07-03-2025
- Business
- Yahoo
Waters Corporation to Present at the Leerink Partners Global Healthcare Conference
MILFORD, Mass., March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11th, 2025 at 10:00AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600 passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Caspar Tudor, Head of Investor Relationsinvestor_relations@ View original content: SOURCE Waters Corporation Sign in to access your portfolio
Yahoo
05-03-2025
- Business
- Yahoo
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
LONDON, March 05, 2025--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit View source version on Contacts Inquiries:Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communicationsir@ Tel: +1 (646) 637-3208 Sign in to access your portfolio
Yahoo
04-03-2025
- Business
- Yahoo
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ('Eledon') (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@ Media Contact: Jenna UrbanCG Life(212) 253 8881jurban@ Source: Eledon Pharmaceuticals
Yahoo
03-03-2025
- Business
- Yahoo
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, March 20, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results and business highlights. The dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating in several upcoming investor conferences: Leerink Partners Global Healthcare Conference: fireside chat on March 10, 2025 37th Annual Roth Conference: investor meetings on March 16-18, 2025 To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be available for 30 days following the event. About ARS Pharmaceuticals, Inc. ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is commercializing ® 2 mg (trade name EUR® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, other allergens, as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit Investor Contacts:Justin Chakma, ARS Pharmaceuticalsjustinc@ Media Contact:Christy Curran, Sam Brown in to access your portfolio
